Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
3.
Am J Pharm Educ ; 75(8): 164, 2011 Oct 10.
Artículo en Inglés | MEDLINE | ID: mdl-22102754

RESUMEN

As colleges and schools of pharmacy develop core courses related to patient safety, course-level outcomes will need to include both knowledge and performance measures. Three key performance outcomes for patient safety coursework, measured at the course level, are the ability to perform root cause analyses and healthcare failure mode effects analyses, and the ability to generate effective safety communications using structured formats such as the Situation-Background-Assessment-Recommendation (SBAR) situational briefing model. Each of these skills is widely used in patient safety work and competence in their use is essential for a pharmacist's ability to contribute as a member of a patient safety team.


Asunto(s)
Competencia Clínica/normas , Comunicación , Curriculum/normas , Seguridad del Paciente/normas , Análisis de Causa Raíz/normas , Educación de Postgrado en Farmacia/métodos , Educación de Postgrado en Farmacia/normas , Humanos , Farmacéuticos/normas , Análisis de Causa Raíz/métodos
5.
Ann Pharmacother ; 40(5): 917-24, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16638920

RESUMEN

OBJECTIVE: To review Public Law (PL) 109-41-the Patient Safety and Quality Improvement Act of 2005 (PSQIA)-and summarize key medication error research that contributed to congressional recognition of the need for this legislation. DATA SOURCES: Relevant publications related to medication error research, patient safety programs, and the legislative history of and commentary on PL 109-41, published in English, were identified by MEDLINE, PREMEDLINE, Thomas (Library of Congress), and Internet search engine-assisted searches using the terms healthcare quality, medication error, patient safety, PL 109-41, and quality improvement. Additional citations were identified from references cited in related publications. STUDY SELECTION AND DATA EXTRACTION: All relevant publications were reviewed. Summarization of the PSQIA was carried out by legal textual analysis. DATA SYNTHESIS: PL 109-41 provides privilege and confidentiality for patient safety work product (PSWP) developed for reporting to patient safety organizations (PSOs). It does not establish federal mandatory reporting of significant errors; rather, it relies on existing state reporting systems. The Act does not preempt stronger state protections for PSWP. The Agency for Healthcare Research and Quality is directed to certify PSOs and promote the establishment of a national network of patient safety databases. Whistleblower protection and penalties for unauthorized disclosure of PSWP are among its enforcement mechanisms. CONCLUSIONS: The Act protects clinicians who report minor errors to PSOs and protects the information from disclosure, but providers must increasingly embrace a culture of interdisciplinary concern for patient safety if this protection is to have real impact on patient care.


Asunto(s)
Legislación de Medicamentos , Errores de Medicación/legislación & jurisprudencia , Garantía de la Calidad de Atención de Salud/legislación & jurisprudencia , Administración de la Seguridad/legislación & jurisprudencia , Bases de Datos Factuales , Humanos , National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division , Garantía de la Calidad de Atención de Salud/organización & administración , Administración de la Seguridad/organización & administración , Estados Unidos , United States Agency for Healthcare Research and Quality/legislación & jurisprudencia
7.
Ann Pharmacother ; 39(2): 346-51, 2005 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-15632221

RESUMEN

The controversy surrounding the potential switch of the Plan B emergency contraceptive therapy from prescription to over-the-counter status has been unprecedented. Regulatory, professional, and societal aspects of this issue have been discussed recently and will no doubt continue to be debated. In this editorial, members of the Medicine, Law, and Ethics panel of The Annals of Pharmacotherapy's Editorial Board offer a sampling of viewpoints touching on varying aspects of the controversy. Readers may wish to consider the ramifications of their professional decisions in this and similar situations in advance of having to make such decisions.


Asunto(s)
Anticonceptivos Poscoito , Levonorgestrel , Medicamentos sin Prescripción , Anticonceptivos Poscoito/provisión & distribución , Humanos , Levonorgestrel/provisión & distribución , Medicamentos sin Prescripción/provisión & distribución
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...